acute severe pain
Pain · 2019–2019
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| oxycodone Acute severe disabling pain unresponsive to non-opioid analgesics, for short-term use (2-3 days). | Jul 2019 | Recommended with restriction | none received |
| oxycodone, tramadol, codeine, hydromorphone, morphine, fentanyl, tapentadol, buprenorphine Short-term management of acute severe pain unresponsive to non-opioid analgesics; management of chronic severe pain in cancer and palliative care settings; and… | Dec 2019 | Recommended with restriction | no section in document |
What the PBS pays
$558M in government benefit over 2024–25, across 14,662,465 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| oxycodone, tramadol, codeine, hydromorphone, morphine, tapentadol, buprenorphine, fentanyl | $440M |
| oxycodone | $117.7M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.